# Canakinumab for Treatment of Adult-onset Still's Disease

> **NCT02204293** · PHASE2 · TERMINATED · sponsor: **Charite University, Berlin, Germany** · enrollment: 36 (actual)

## Conditions studied

- Adult-Onset Still´s Disease

## Interventions

- **DRUG:** Canakinumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02204293
- **Lead sponsor:** Charite University, Berlin, Germany
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-06-21
- **Primary completion:** 2018-05-05
- **Final completion:** 2018-05-05
- **Target enrollment:** 36 (ACTUAL)
- **Why stopped:** Recruitment issues due to marketing authorization of study drug
- **Last updated:** 2020-08-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02204293

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02204293, "Canakinumab for Treatment of Adult-onset Still's Disease". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02204293. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*